Copenhagen, Denmark, November 6th, 2020 – – Vipergen ApS announced today the commercial release of the first technology for screening of DNA-encoded small molecule libraries (DELs) inside a living cell. This proprietary technology will significantly accelerate and improve the drug discovery process. Main attributes include, 1) lowering the attrition rate in drug discovery since the screening is performed under physiological relevant conditions, and 2) expanding the DEL amenable target space since no requirement for highly purified active target protein. Vipergen is offering small molecule drug discovery services employing the technology under different business models, including simple Fee-For-Service
“We are very excited about this transformative technology which is a major step forward for the fast-growing field of small molecule drug discovery based on DELs.” said Nils Hansen, Chief Executive Officer of Vipergen. “Vipergen is now able to screen a wider range of challenging target proteins and a lower attrition rate is expected because we screen under physiological relevant conditions. Furthermore, this technology uniquely allows us to engage in large scale screenings campaigns of hundreds, even thousands of protein targets per year, because the input is the target gene, and thereby eliminates the need for purified active protein, which require work, are more delicate, and require tailor-made screening conditions.”
About Vipergen ApS
Vipergen is a world leading provider of small molecule drug discovery services based on DNAencoded library (DEL) technologies
Vipergen is finding tractable hits/leads for your pharmaceutical relevant targets, using three proprietary 2nd and 3rd generation DEL technologies
Vipergen is offering different business models, including simple Fee-For-Service. In 2015-20 >40 deals signed, including with top-5 pharma in both USA, EU and Japan
For further details about Vipergen and the YoctoReactor® / Binder Trap Enrichment® drug discovery technology platforms please visit www.vipergen.com or contact:
Vipergen ApS
Dr. Nils Hansen,
Chief Executive Officer
Phone: +45 2523 6680
nha@vipergen.com